Using engineered stem cell-derived vesicles to treat type 1 diabetes
Engineered extracellular vesicles derived from mesenchymal stem cells for the treatment of type 1 diabetes
This study is exploring a new treatment using specially designed tiny particles from stem cells to help the immune system be kinder to insulin-producing cells in people with type 1 diabetes, aiming to improve current therapies for those who haven't found success with them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11058405 on NIH RePORTER |
What this research studies
This research investigates the use of engineered extracellular vesicles derived from mesenchymal stem cells to promote immune tolerance in patients with type 1 diabetes (T1D). The approach focuses on enhancing the PD-1/PD-L1 immune checkpoint pathway, which is crucial for maintaining immune balance and preventing the destruction of insulin-producing beta cells. By genetically modifying these vesicles, the research aims to improve the efficacy of existing therapies, such as anti-CD3 monoclonal antibodies, and address the limitations faced by patients who do not respond to current treatments. Patients may benefit from a novel therapeutic option that could lead to better management of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes, particularly those who are newly diagnosed or have relatives at high risk for developing the condition.
Not a fit: Patients with type 2 diabetes or those who do not have an autoimmune component to their diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that helps preserve insulin production and improve blood sugar control for patients with type 1 diabetes.
How similar studies have performed: Previous research has shown promising results with similar immune tolerance approaches, particularly using anti-CD3 therapies, indicating potential for success in this novel application.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Lee, Ryang Hwa — Texas A&m University Health Science Ctr
- Study coordinator: Lee, Ryang Hwa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.